Department of Psychiatry, Mayo Clinic Health System, Eau Claire, Wisconsin,
Department of Psychiatry, Mayo Clinic Health System, Eau Claire, Wisconsin.
WMJ. 2022 Apr;121(1):E1-E4.
Phenibut is a psychoactive drug with GABA agonism. It remains unregulated and easily attainable in the United States, where it has become a novel drug of abuse.
We present the case of a 34-year-old man who used phenibut consistently for 3 years. After 6 months of use, he developed signs of dependence and failed outpatient detoxification. While taking high doses, he experienced parasomnia-like symptoms and periods of dysexecutive function. After abrupt cessation, he developed severe withdrawal symptoms, was hospitalized, and required intubation. His condition improved after 1 week of treatment. After recovery and discharge, he remains stable utilizing an extended taper of acamprosate and baclofen.
Phenibut is not detected on urine drug screen and withdrawal symptoms are nonspecific. Optimal treatment of withdrawal remains unknown. Baclofen and phenobarbital have been successful for treatment of dependence.
Clinicians should be aware of phenibut abuse and the potential for dependence and withdrawal.
苯环利定是一种具有 GABA 激动作用的精神活性药物。它在美国不受管制且易于获得，已成为一种新型滥用药物。
我们介绍了一位 34 岁的男性患者，他持续使用苯环利定 3 年。使用 6 个月后，他出现了依赖的迹象，并未能通过门诊戒毒。在服用高剂量时，他出现了类似睡眠障碍的症状和执行功能障碍期。突然停药后，他出现了严重的戒断症状，住院并需要插管。经过 1 周的治疗后，他的病情有所改善。康复出院后，他通过延长使用安非他酮和巴氯芬的剂量来稳定病情。
尿液药物筛查无法检测到苯环利定，且戒断症状不具有特异性。最佳的戒断治疗方法仍不清楚。巴氯芬和苯巴比妥已成功用于治疗依赖。
临床医生应意识到苯环利定的滥用以及产生依赖和戒断的可能性。
